Literature DB >> 27428296

Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study.

Sigurd Broesby-Olsen1,2, Dóra Körmendiné Farkas3, Hanne Vestergaard4,5, Anne Pernille Hermann4,6, Michael Boe Møller4,7, Charlotte Gotthard Mortz8,4, Thomas Kielsgaard Kristensen4,7, Carsten Bindslev-Jensen8,4, Henrik Toft Sørensen3, Henrik Frederiksen4,3,5.   

Abstract

In patients with systemic mastocytosis (SM), several aspects of morbidity remain poorly understood. We assessed the risk of solid cancers, cardiovascular disease, anaphylaxis, osteoporosis, and fractures in SM patients. Using Danish medical registries, we conducted a nationwide population-based cohort study including 687 adult (≥15 years) SM patients diagnosed during 1997-2012. A comparison cohort of 68,700 subjects from the general Danish population who were alive and without SM at the given SM subject's diagnosis were age- and gender-matched. Outcomes were a new diagnosis of solid cancer, venous thromboembolism (VTE), myocardial infarction (MI), stroke, anaphylaxis, osteoporosis, or fracture. For solid cancers the hazard ratio (HR) was 2.4 (95% confidence interval [CI] 1.9-2.8) with a 10-year absolute risk (AR) in the SM-cohort of 12.6% (95% CI 9.4-16.3). Specifically, we found a HR of 7.5 (95% CI 4.4-13.0) for melanoma and a HR of 2.5 (95% CI 1.7-3.5) for non-melanoma skin cancers (NMSCs). For VTE we found a HR of 1.9 (95% CI 1.2-3.0), with a 10-year AR of 3.9% (95% CI 2.3-6.1); for MI a nonsignificant increased HR of 1.4 (95% CI 0.9-2.3), with a 10-year AR of 1.8% (95% CI 0.9-3.2); and for stroke a HR of 1.6 (95% CI 1.1-2.3) with a 10-year AR of 4.6% (95% CI 2.8-6.9). The HR for anaphylaxis was 7.2 (95% CI 5.3-9.9), and the 10-year AR was 3.1% (95% CI 1.9-4.9). For osteoporosis the HR was 3.6 (95% CI 2.7-4.6) with a 10-year AR of 7.2% (95% CI 5.2-9.8). For fractures the HR was 1.2 (95% CI 0.9-1.6) and the 10-year AR was 5.9% (95% CI 3.9-8.4). SM patients are at increased risk of solid cancers - especially melanoma and NMSC-and cardiovascular disease. The risk of anaphylaxis and osteoporosis is clearly increased in SM, though absolute risk was low in this population-based study. The fracture-risk was only slightly increased. Am. J. Hematol. 91:1069-1075, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27428296     DOI: 10.1002/ajh.24490

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

Review 1.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

Review 2.  Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.

Authors:  Peter Valent; Patrizia Bonadonna; Karin Hartmann; Sigurd Broesby-Olsen; Knut Brockow; Joseph H Butterfield; Massimo Triggiani; Jonathan J Lyons; Joanna N G Oude Elberink; Michel Arock; Dean D Metcalfe; Cem Akin
Journal:  Int Arch Allergy Immunol       Date:  2019-06-28       Impact factor: 2.749

3.  Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.

Authors:  Giulia Carosi; Gregorio Guabello; Matteo Longhi; Federica Grifoni; Elena Passeri; Sabrina Corbetta
Journal:  Mediators Inflamm       Date:  2020-10-20       Impact factor: 4.711

4.  How "benign" is cutaneous mastocytosis? A Danish registry-based matched cohort study.

Authors:  Line Kibsgaard; Mette Deleuran; Carsten Flohr; Sinéad Langan; Anne Braae Olesen; Christian Vestergaard
Journal:  Int J Womens Dermatol       Date:  2020-06-01

5.  Safe administration of chemotherapy in mast cell activation syndrome.

Authors:  M P Lythgoe; J Krell; I A McNeish; L Tookman
Journal:  J Oncol Pharm Pract       Date:  2020-10-09       Impact factor: 1.809

6.  Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA.

Authors:  Gerhard J Molderings; Thomas Zienkiewicz; Jürgen Homann; Markus Menzen; Lawrence B Afrin
Journal:  F1000Res       Date:  2017-10-26

7.  Tumor Suppressors-HTRA Proteases and Interleukin-12-in Pediatric Asthma and Allergic Rhinitis Patients.

Authors:  Joanna Renke; Eliza Wasilewska; Sabina Kędzierska-Mieszkowska; Katarzyna Zorena; Sylwia Barańska; Tomasz Wenta; Anna Liberek; Danuta Siluk; Dorota Żurawa-Janicka; Aleksandra Szczepankiewicz; Marcin Renke; Barbara Lipińska
Journal:  Medicina (Kaunas)       Date:  2020-06-17       Impact factor: 2.430

8.  Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: The results of a double-blind, placebo-controlled challenge study.

Authors:  M A W Hermans; S Q A van der Vet; P M van Hagen; R Gerth van Wijk; P L A van Daele
Journal:  Allergy       Date:  2018-10       Impact factor: 13.146

9.  Sampling strategies for selecting general population comparison cohorts.

Authors:  Uffe Heide-Jørgensen; Kasper Adelborg; Johnny Kahlert; Henrik Toft Sørensen; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2018-09-25       Impact factor: 4.790

Review 10.  Melanoma and Mastocytosis.

Authors:  Aleksandra Vojvodic; Tatjana Vlaskovic-Jovicevic; Petar Vojvodic; Jovana Vojvodic; Mohamad Goldust; Zorica Peric-Hajzler; Dusica Matovic; Goran Sijan; Nenad Stepic; Uwe Wollina; Massimo Fioranelli; Michael Tirant; Van Thuong Nguyen; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2019-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.